Literature DB >> 30186502

Acute bilateral vision deficit as the initial symptom in Guillain-Barre syndrome: A case report.

Hui-Jun Wen1.   

Abstract

Guillain-Barre syndrome (GBS) is a rare autoimmune-mediated peripheral neuropathy with an acute onset. GBS is associated with posterior cranial nerve injury including the facial, oculomotor, glossopharyngeal and vagus nerves. A 43-year-old female presented with worsening blurred binocular vision accompanied by diplopia, bilateral ptosis, speech difficulties, dysphagia, extremity numbness and weakness of the limbs. A neurological examination was conducted along with magnetic resonance imaging of the brain and spinal cord, electromyography, cerebrospinal fluid analysis and visual evoked potential tests, which led to a diagnosis of GBS. Following immunoglobulin administration, the patient's neurological deficiencies were markedly relieved and they were discharged following a 3-week observation period. To the best of our knowledge, this is the first reported case of GBS associated with cranial nerve damage presenting with bilateral visual deterioration as the initial symptom. It is necessary to emphasize that early diagnosis and commencing the immunological treatment in a timely manner resulted in a favorable prognosis for the patient.

Entities:  

Keywords:  Guillain-Barre syndrome; autoimmune polyneuropathy; multiple cranial nerve damage; visual deterioration

Year:  2018        PMID: 30186502      PMCID: PMC6122450          DOI: 10.3892/etm.2018.6465

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

1.  Case 14: a woman with bilateral Bell's palsy.

Authors:  Michael S Rafii
Journal:  MedGenMed       Date:  2006-10-31

Review 2.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

3.  Papilloedema and the Landry-Guillain-Barré syndrome. Case reports and a review.

Authors:  J B Morley; E H Reynolds
Journal:  Brain       Date:  1966-06       Impact factor: 13.501

Review 4.  Plasma exchange for Guillain-Barré syndrome.

Authors:  Jean Claude Raphaël; Sylvie Chevret; Richard A C Hughes; Djillali Annane
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  [Intravenous immunoglobulin (IVIG)].

Authors:  Masako Hara
Journal:  Nihon Rinsho       Date:  2009-03

6.  Acute multiple cranial neuropathy: a variant of Guillain-Barré syndrome?

Authors:  Rong-Kuo Lyu; Sien-Tsong Chen
Journal:  Muscle Nerve       Date:  2004-10       Impact factor: 3.217

7.  Polyneuritis cranialis presenting with anti-GQ1b IgG antibody.

Authors:  Bengt Edvardsson; Staffan Persson
Journal:  J Neurol Sci       Date:  2009-03-25       Impact factor: 3.181

Review 8.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

9.  Guillain-Barré syndrome: clinical profile and management.

Authors:  Sreenivasa Rao Sudulagunta; Mahesh Babu Sodalagunta; Mona Sepehrar; Hadi Khorram; Shiva Kumar Bangalore Raja; Shyamala Kothandapani; Zahra Noroozpour; Mohammed Aheta Sham; Nagendra Prasad; Sony Parethu Sunny; Munawar Dhanish Mohammed; Rekha Gangadharappa; Ranjitha Nidsale Sudarshan
Journal:  Ger Med Sci       Date:  2015-09-21

10.  Multiple cranial neuropathies without limb involvements: guillain-barre syndrome variant?

Authors:  Ju Young Yu; Han Young Jung; Chang Hwan Kim; Hyo Sang Kim; Myeong Ok Kim
Journal:  Ann Rehabil Med       Date:  2013-10-29
View more
  1 in total

1.  Case Report: Intracranial Hypertension Secondary to Guillain-Barre Syndrome.

Authors:  Christina Doxaki; Eleftheria Papadopoulou; Iliana Maniadaki; Nikolaos G Tsakalis; Konstantinos Palikaras; Pelagia Vorgia
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.